Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
Joint Authors
Fontana, Joseph A.
Vaishampayan, Ulka
Smith, Daryn
Freeman, Stacy
Heilbrun, Lance K.
Heath, Elisabeth I.
Baranowski, Karen
Ogita, Shin
Tejwani, Sheela
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-06-13
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Introduction/Background.
Nonmetastatic castrate resistant prostate cancer (CRPC) is a challenging disease state.
The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients.
Patients.
Patients with prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases and PSA progression despite androgen deprivation therapy.
Methods.
Bevacizumab 10 mg/kg intravenously was administered every 14 days until PSA progression, development of metastasis, or unacceptable toxicity.
Results.
15 patients were enrolled and treated with bevacizumab for a median duration of 3.1 months.
Median baseline PSA was 27 ng/mL, and seven patients had Gleason Score ≥8.
Five patients had declined in PSA during the treatment.
Median PSA doubling time was prolonged from 4.7 months pretreatment to 6.5 months.
Median time to PSA progression and new metastasis were 2.8 and 7.9 months, respectively.
There were three grade 3 adverse events (one proteinuria and two hypertension) and one pulmonary embolism.
There was no treatment-related mortality.
Conclusion.
Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC, and investigation of novel strategies is needed.
American Psychological Association (APA)
Ogita, Shin& Tejwani, Sheela& Heilbrun, Lance K.& Fontana, Joseph A.& Heath, Elisabeth I.& Freeman, Stacy…[et al.]. 2012. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology،Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-456746
Modern Language Association (MLA)
Ogita, Shin…[et al.]. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology No. 2012 (2012), pp.1-7.
https://search.emarefa.net/detail/BIM-456746
American Medical Association (AMA)
Ogita, Shin& Tejwani, Sheela& Heilbrun, Lance K.& Fontana, Joseph A.& Heath, Elisabeth I.& Freeman, Stacy…[et al.]. Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-7.
https://search.emarefa.net/detail/BIM-456746
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-456746